CoChat

Polyunsaturated Fatty Acids, Inflammation, and Cardiovascular Disease: Time to Widen Our View of the Mechanisms

Sacks, Frank M., Campos, Hannia · 2006 · The Journal of Clinical Endocrinology & Metabolism
Cited by 86

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

For at least 50 yr, polyunsaturated fatty acids (PUFAs) have been studied intensively as nutrients that protect against cardiovascular disease (CVD). As new mechanisms have been identified, research and clinical emphasis have shifted from one type of PUFA to another. As a class, PUFAs vary in several characteristics, namely length of the carbon chain from 18 to 22 carbons, number of double bonds between carbon atoms, and the position of the first double bond in the chain denoted as omega-6 or omega-3 (alternatively, n-6 or n-3). The double bonds, as few as two or as many as six, are located in a series beginning at either the third or the sixth carbon atom from the methyl end of the molecule and extending toward the carboxyl group. The biological properties of PUFAs are related to these three characteristics, although not necessarily in a uniform way, as we will discuss. In 1956–1957, four research groups published convincing experiments showing that linoleic acid (18 carbons, 2 double bonds, omega-6) substantially reduced serum cholesterol, and it remains the most potent cholesterol-lowering nutrient (reviewed in Ref.1). Lacking medications to treat hypercholesterolemia, high-linoleic acid vegetable oils were a mainstay of serum cholesterol treatment in the 1950s and 1960s, with patients daily swilling corn, sunflower, safflower, or soybean oils. The potential of linoleic acid to reduce CVD was put to a rigorous test in randomized clinical trials, and reduction in definite clinical cardiovascular endpoints was established in the range of 20–35%, in line with the serum cholesterol reduction that was achieved (1). Prospective epidemiological studies in very large populations confirmed that dietary linoleic acid is predictive of reduced CVD (2). Thus, one paradigm became established, that linoleic acid, an omega-6 PUFA, is cardioprotective. Because two double carbon bonds in an 18-carbon fatty acid were so effective, then what about fatty acids with five or six double bonds in 20- or 22-carbon atoms? What about shifting the series of double bonds from omega-6 to omega-3? Unfortunately, neither more carbons, more double bonds, nor the omega-3 isomer improve blood cholesterol reduction. In fact, eicosapentaenoic acid (EPA) (20 carbons, 5 double bonds, omega-3) or docosahexaenoic acid (DHA)(22 carbons, 6 double bonds, omega-3), found in fish oils, given in doses less than 6 g/d (equivalent to 12–20 1-g fish oil capsules per day) increase low-density lipoprotein (LDL) cholesterol levels (3, 4). When large amounts of fish oil (containing 24 g of omega-3 fatty acid per day) replace saturated fat, lower LDL cholesterol levels are observed, similar to the effects of vegetable oil (5). In contrast, EPA and DHA are much more potent than linoleic acid for lowering plasma triglycerides (6). The molecular mechanisms mediating these effects of PUFAs on serum cholesterol and CVD are still not fully understood. Thus, linoleic acid remains the most effective PUFA for lowering serum cholesterol and the fatty acid most well established to prevent CVD. Readers may find themselves surprised at this last statement in view of the dominance of the omega-3 PUFA theory in basic and clinical research. In the early 1980s, two lines of evidence coalesced to engender widespread excitement on the potentially cardioprotective effects of omega-3 fatty acids, particularly those from fish oil (EPA and DHA). Populations eating large amounts of fatty fish had low rates of CVD, and in many epidemiological studies, n-3 PUFA intake or blood levels are inversely related to CVD (7). Omega-3 fatty acids are metabolized to prostaglandins and leukotrienes that are antithrombotic, antiinflammatory, and vasodilating. The omega-3-cyclooxygenase-lipoxygenase paradigm came to include a negative view of omega-6 PUFA (8). The theory considered the fact that dietary linoleic acid can be metabolized to arachidonic acid that can be metabolized further to prostaglandins and leukotrienes that are relatively prothrombotic, proinflammatory, and vasoconstricting. Also, n-6 PUFAs may reduce by competition for cyclooxygenase the formation of antiinflammatory mediators from n-3 PUFAs. Carried to its extreme, the theory called for the ideal fatty acid balance to be high in omega-3 and low in omega-6, producing a high omega-3 to omega-6 ratio. This vision was restricted because it did not recognize the known benefits of linoleic acid on LDL cholesterol and CVD. The established benefits of omega-6 PUFAs raise the question that if omega-6 PUFAs are capable of being metabolized to undesirable prostaglandins and leukotrienes, why should they protect against CVD? One explanation is that LDL cholesterol is such a dominant force in atherosclerosis, effects on prostanoids are not completely offsetting. Another explanation is that omega-6 dietary PUFAs ordinarily in vivo may be minimally involved in cyclooxygenase reactions and do not stimulate appreciably the production of vasoact

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2005-2459

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 86

Metadata

Authors
Sacks, F. M., & Campos, H.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2006-02-01
Volume
91
Issue
2
Pages
398-400
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2156015457
Cited by
86
References
3
FWCI
6.14
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Polyunsaturated Fatty Acids, Inflammation, and Cardiovascular Disease: Time to Widen Our View of the Mechanisms. https://app.cochat.ai/papers/10.1210/jc.2005-2459
The paper
Sacks, F. M., & Campos, H. (2006). Polyunsaturated Fatty Acids, Inflammation, and Cardiovascular Disease: Time to Widen Our View of the Mechanisms. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2005-2459

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.